Elixiron Immunotherapeutics

Elixiron Immunotherapeutics (Cayman) Limited is a clinical-stage biopharmaceutical company founded in 2017, with offices in Taipei, Taiwan and Cambridge, Massachusetts, developing precision immunotherapies for neuroinflammation, autoimmune disease and cancer. Its clinical pipeline is led by enrupatinib (EI-1071), a small-molecule CSF-1R inhibitor in development for Alzheimer's disease and other neurodegenerative indications, and EI-001, a fully human anti-interferon-gamma monoclonal antibody in Phase 2 for vitiligo, alongside preclinical EI-012 (anti-CD36) and EI-220 (mRNA) oncology programs. The company publishes a corporate and investor-relations website only: there is no developer portal, public API, SDK, webhook surface or machine-readable specification of any kind on its own hosts.

Elixiron Immunotherapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunotherapy, and Life Sciences.

Elixiron Immunotherapeutics’ developer surface includes product news and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub

6.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsImmunotherapyLife SciencesClinical TrialsHealthcareTaiwan

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 6.0/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/elixiron-immunotherapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 4

The organization behind the API

Website

Website

About

About

News

News

LinkedIn

Source (apis.yml)

aid: elixiron-immunotherapeutics
name: Elixiron Immunotherapeutics
description: 'Elixiron Immunotherapeutics (Cayman) Limited is a clinical-stage biopharmaceutical company founded in 2017,
  with offices in Taipei, Taiwan and Cambridge, Massachusetts, developing precision immunotherapies for neuroinflammation,
  autoimmune disease and cancer. Its clinical pipeline is led by enrupatinib (EI-1071), a small-molecule CSF-1R inhibitor
  in development for Alzheimer''s disease and other neurodegenerative indications, and EI-001, a fully human anti-interferon-gamma
  monoclonal antibody in Phase 2 for vitiligo, alongside preclinical EI-012 (anti-CD36) and EI-220 (mRNA) oncology programs.
  The company publishes a corporate and investor-relations website only: there is no developer portal, public API, SDK, webhook
  surface or machine-readable specification of any kind on its own hosts.'
url: https://raw.githubusercontent.com/api-evangelist/elixiron-immunotherapeutics/refs/heads/main/apis.yml
image: https://elixiron.com/dist/images/common/og.jpg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunotherapy
- Life Sciences
- Clinical Trials
- Healthcare
- Taiwan
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/elixiron-immunotherapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/elixiron-immunotherapeutics-llms.txt
- type: Website
  url: https://elixiron.com/
- type: About
  url: https://elixiron.com/about.php
- type: Contact
  url: https://elixiron.com/contact.php
- type: News
  url: https://elixiron.com/news.php
- type: LinkedIn
  url: https://www.linkedin.com/company/elixiron-immunotherapeutics
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Elixiron Immunotherapeutics is a clinical-stage biopharmaceutical company whose only production host, elixiron.com,
    serves a PHP corporate and investor-relations site whose 57-URL sitemap contains no developer, API or documentation page
    at all.
  evidence:
  - url: https://elixiron.com/sitemap.xml
    status: 200
  - url: https://elixiron.com/openapi.json
    status: 404
  - url: https://elixiron.com/.well-known/agent-card.json
    status: 404
  - url: https://elixiron.com/llms.txt
    status: 404
  checked: '2026-08-12'